Trial · NCT07911397
Prospective AI-Assisted Screening of Biliary Tract Cancer Using Non-Contrast CT
NCT07911397, Not applicable, Not yet recruiting, Beijing Tsinghua Chang Gung Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Prospective AI-Assisted Screening of Biliary Tract Cancer Using Non-Contrast CT. Trials, record NCT07911397. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07911397
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Prospective AI-Assisted Screening of Biliary Tract Cancer Using Non-Contrast CT
- NCT number
- NCT07911397
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 10,000 participants, estimated
- Lead sponsor
- Beijing Tsinghua Chang Gung Hospital
- Conditions
- Biliary Tract Cancer (BTC)
- Interventions
- AI-Assisted Biliary Tract Cancer Screening Using NCCT
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Patient-level area under the receiver operating characteristic curve (AUC) of the AI system for distinguishing biliary tract cancer from non-biliary-tract-cancer cases using non-contrast computed tomography (NCCT) | From the index NCCT examination to completion of the reference standard assessment, up to 30 days | The primary outcome is the patient-level area under the receiver operating characteristic curve (AUC) for the AI system in distinguishing biliary tract cancer from non-biliary-tract-cancer cases using non-contrast computed tomography (NCCT). Biliary tract cancer includes intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, distal cholangiocarcinoma, and gallbladder cancer. The reference diagnosis will be established using the predefined clinical reference standard. |
| Secondary | Sensitivity of the AI system for detecting biliary tract cancer | From the index NCCT examination to completion of the reference standard assessment, up to 30 days | Sensitivity of the AI system for identifying patients with biliary tract cancer using non-contrast computed tomography (NCCT), based on the predefined clinical reference standard. Biliary tract cancer includes intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, distal cholangiocarcinoma, and gallbladder cancer. |
| Secondary | Specificity of the AI system for identifying non-biliary-tract-cancer cases | From the index NCCT examination to completion of the reference standard assessment, up to 30 days | Specificity of the AI system for identifying patients without biliary tract cancer using non-contrast computed tomography (NCCT), based on the predefined clinical reference standard. |
| Secondary | Positive predictive value of the AI system for biliary tract cancer | From the index NCCT examination to completion of the reference standard assessment, up to 30 days | Positive predictive value of the AI system for identifying biliary tract cancer using non-contrast computed tomography (NCCT), based on the predefined clinical reference standard. |
| Secondary | Negative predictive value of the AI system for biliary tract cancer | From the index NCCT examination to completion of the reference standard assessment, up to 30 days | Negative predictive value of the AI system for excluding biliary tract cancer using non-contrast computed tomography (NCCT), based on the predefined clinical reference standard. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07911397
GET https://conductscience.org/api/trials/v1/NCT07911397/registered